MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Depression"

  • 2019 International Congress

    Electroconvulsive Therapy (ECT): An Effective Option for the Treatment of Medication-Resistant Psychiatric Symptoms in Huntington’s Disease: A Case Series and Review of the Literature

    J. Adrissi, N. Nadkarni, E. Gausche, D. Bega (Chicago, IL, USA)

    Objective: Through a single site case series, we investigate the use and effectiveness of electroconvulsive therapy (ECT) for the treatment of refractory psychiatric symptoms in…
  • 2019 International Congress

    Identifying the association of depression and distress in Pakistani patients diagnosed with Parkinsonism syndrome

    A. Fatima (Lahore, Pakistan)

    Objective: Our study aims to identify depression and distress among Pakistani patients diagnosed with Parkinsonism syndrome. We also aim to find out the relationship among depression, distress caused Parkinsonism syndrome.…
  • 2019 International Congress

    Trust the Patient’s Report, not the Doctor’s: Non-Motor Symptoms and Quality of Life in Cervical Dystonia

    I. Ndukwe, J. Dover, P. Lynch, C. O'Neill, S. O'Riordan, M. Hutchinson (Dublin, Ireland)

    Objective: To assess the prevalence of mood disorder and measure health-related quality of life (Hr-QoL) in relation to, pain, disability and disease severity in cervical…
  • 2019 International Congress

    Gene Expression Profiling of depression in Huntington’s disease

    G. Colpo, N. Rocha, E. Furr Stimming, A. Lucio (Houston, TX, USA)

    Objective: This preliminary study was designed to investigate the gene expression profile by RNA-seq in HD patients with depression and without depression, and between subjects…
  • 2019 International Congress

    Predictors of Health-Related Quality of Life in Patients with Cervical Dystonia

    SA. Reijneveld, Z. Gdovinova, MAJ. Tijssen, JP. van Dijk, T. Hoekstra, M. Turcanova Koprusakova, M. Smit, M. Skorvanek, V. Han (Martin, Slovakia)

    Objective: The aim of our study was to assess the prevalence of non-motor symptoms (NMS) and to explore their association with health-related quality of life…
  • 2019 International Congress

    Deep phenotyping adult onset isolated cervical dystonia; the importance of symptomatic anxiety and depression.

    I. Ndukwe, J. Dover, P. Lynch, F. O'Keeffe, S. O'Riordan, M. Hutchinson (Dublin, Ireland)

    Objective: Objective:We aimed to characterise the demographic and clinical aspects of cervical dystonia (CD) patients with symptomatic anxiety and depression. We hypothesised that these patients…
  • 2019 International Congress

    Efficacy and safety of the 5-Hydroxytryptophan on Depression and Apathy in Idiopathic Parkinson’s disease.

    M. Meloni, M. Puligheddu, M. Carta, M. Figorilli, G. Defazio (Cagliari, Italy)

    Objective: The purpose of this study was to compare the effects of 5-HTP to placebo on depression and apathy in patients with PD. Background: Parkinson’s…
  • 2019 International Congress

    Gender differences in Motor symptoms, Non-Motor symptoms and Quality of Life in Parkinson’s disease: COPPADIS-2015 study cohort

    M. Aguilar, P. Pastor, B. Solano, I. Cabo, MJ. Catalan, V. Nogueira, V. Puente, JM. Garcia, R. Perez, C. Borrué, M. Mata, M. Alvarez, AB. Rodriguez, L. Vela, Y. Macías, MJ. Marti, P. Martinez, D. Santos (Sabadell, Spain)

    Objective: To assess gender differences among PD patients and health controls (HC) of the COPPADIS-2015 study cohort. Background: Men and women are different in genetic,…
  • 2019 International Congress

    The effect of istradefylline on mood disorders in Parkinson’s disease

    H. Nagayama, O. Kano, H. Murakami, M. Hamada, R. Sengoku, Y. Shim, T. Toda (Tokyo, Japan)

    Objective: The effectiveness of istradefylline for treatment of mood disorders in patients with Parkinson's disease (PD) was examined in an open-label trial. Background: Depression is…
  • 2019 International Congress

    Open-Label Study of Pimavanserin Patients With Comorbid Parkinson’s Disease and Depression

    J. Norton, D. Fredericks, G. Alva, J. Aldred, B. Coate, D. Dekarske, M. Cantillon, R. Owen (San Deigo, CA, USA)

    Objective: We are assessing use of pimavanserin (PIM) for treatment of depression in adults with PD. Background: Depression occurs in ~50% of Parkinson’s disease (PD)…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 32
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • #25062 (not found)
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley